The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
Abstract Inclisiran, a small interfering RNA, selectively inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis in the liver and has been shown to reduce low‐density lipoprotein cholesterol (LDL‐C) by ≥50% in patients with hypercholesterolemia receiving maximally tolerated statins...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.1080 |
| _version_ | 1827969584750133248 |
|---|---|
| author | Dario Lehoux David Kallend Peter L. J. Wijngaard Alan P. Brown Brad Zerler |
| author_facet | Dario Lehoux David Kallend Peter L. J. Wijngaard Alan P. Brown Brad Zerler |
| author_sort | Dario Lehoux |
| collection | DOAJ |
| description | Abstract Inclisiran, a small interfering RNA, selectively inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis in the liver and has been shown to reduce low‐density lipoprotein cholesterol (LDL‐C) by ≥50% in patients with hypercholesterolemia receiving maximally tolerated statins. The toxicokinetic, pharmacodynamic, and safety profiles of inclisiran when coadministered with a statin were characterized in cynomolgus monkeys. Six cohorts of monkeys were administered either atorvastatin (40 mg/kg, reduced to 25 mg/kg during the study, daily, oral gavage), inclisiran (300 mg/kg every 28 days, subcutaneous administration), atorvastatin (40/25 mg/kg) and inclisiran combinations (30, 100, or 300 mg/kg), or control vehicles over 85 days followed by 90 days' recovery. Inclisiran and atorvastatin toxicokinetic parameters were similar in cohorts administered either agent alone or in combination. Inclisiran exposure increased in a dose‐proportional manner. At Day 86, atorvastatin increased plasma PCSK9 levels four‐fold from pretreatment levels but did not significantly lower serum LDL‐C levels. Inclisiran (alone or in combination) reduced PCSK9 (mean decrease 66–85%) and LDL‐C (mean decrease 65–92%) from pretreatment levels at Day 86; levels were significantly lower than the control group (p ≤ .05) and remained decreased during the 90‐day recovery. Coadministration of inclisiran with atorvastatin resulted in greater reductions in LDL‐C and total cholesterol compared with either drug alone. No toxicities or adverse effects were observed in any cohort receiving inclisiran, either alone or in combination. In summary, inclisiran significantly inhibited PCSK9 synthesis and decreased LDL‐C in cynomolgus monkeys without increasing the risk of adverse effects when coadministered with atorvastatin. |
| first_indexed | 2024-04-09T18:39:58Z |
| format | Article |
| id | doaj.art-b10d010fc2974f3d86fce60390f08379 |
| institution | Directory Open Access Journal |
| issn | 2052-1707 |
| language | English |
| last_indexed | 2024-04-09T18:39:58Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pharmacology Research & Perspectives |
| spelling | doaj.art-b10d010fc2974f3d86fce60390f083792023-04-11T06:38:37ZengWileyPharmacology Research & Perspectives2052-17072023-04-01112n/an/a10.1002/prp2.1080The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductionsDario Lehoux0David Kallend1Peter L. J. Wijngaard2Alan P. Brown3Brad Zerler4Targanta Therapeutics Inc. Saint Laurent Quebec CanadaThe Medicines Company (Schweiz) GmbH Zurich SwitzerlandThe Medicines Company Inc Parsippany New Jersey USANovartis Institutes for Biomedical Research Cambridge Massachusetts USAThe Medicines Company Inc Parsippany New Jersey USAAbstract Inclisiran, a small interfering RNA, selectively inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis in the liver and has been shown to reduce low‐density lipoprotein cholesterol (LDL‐C) by ≥50% in patients with hypercholesterolemia receiving maximally tolerated statins. The toxicokinetic, pharmacodynamic, and safety profiles of inclisiran when coadministered with a statin were characterized in cynomolgus monkeys. Six cohorts of monkeys were administered either atorvastatin (40 mg/kg, reduced to 25 mg/kg during the study, daily, oral gavage), inclisiran (300 mg/kg every 28 days, subcutaneous administration), atorvastatin (40/25 mg/kg) and inclisiran combinations (30, 100, or 300 mg/kg), or control vehicles over 85 days followed by 90 days' recovery. Inclisiran and atorvastatin toxicokinetic parameters were similar in cohorts administered either agent alone or in combination. Inclisiran exposure increased in a dose‐proportional manner. At Day 86, atorvastatin increased plasma PCSK9 levels four‐fold from pretreatment levels but did not significantly lower serum LDL‐C levels. Inclisiran (alone or in combination) reduced PCSK9 (mean decrease 66–85%) and LDL‐C (mean decrease 65–92%) from pretreatment levels at Day 86; levels were significantly lower than the control group (p ≤ .05) and remained decreased during the 90‐day recovery. Coadministration of inclisiran with atorvastatin resulted in greater reductions in LDL‐C and total cholesterol compared with either drug alone. No toxicities or adverse effects were observed in any cohort receiving inclisiran, either alone or in combination. In summary, inclisiran significantly inhibited PCSK9 synthesis and decreased LDL‐C in cynomolgus monkeys without increasing the risk of adverse effects when coadministered with atorvastatin.https://doi.org/10.1002/prp2.1080hydroxymethylglutaryl‐coenzyme a reductase inhibitorshypercholesterolemiaLDL cholesterolPCSK9 inhibitors |
| spellingShingle | Dario Lehoux David Kallend Peter L. J. Wijngaard Alan P. Brown Brad Zerler The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions Pharmacology Research & Perspectives hydroxymethylglutaryl‐coenzyme a reductase inhibitors hypercholesterolemia LDL cholesterol PCSK9 inhibitors |
| title | The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions |
| title_full | The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions |
| title_fullStr | The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions |
| title_full_unstemmed | The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions |
| title_short | The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions |
| title_sort | n acetylgalactosamine conjugated small interfering rna inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low density lipoprotein cholesterol reductions |
| topic | hydroxymethylglutaryl‐coenzyme a reductase inhibitors hypercholesterolemia LDL cholesterol PCSK9 inhibitors |
| url | https://doi.org/10.1002/prp2.1080 |
| work_keys_str_mv | AT dariolehoux thenacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT davidkallend thenacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT peterljwijngaard thenacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT alanpbrown thenacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT bradzerler thenacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT dariolehoux nacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT davidkallend nacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT peterljwijngaard nacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT alanpbrown nacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions AT bradzerler nacetylgalactosamineconjugatedsmallinterferingrnainclisirancanbecoadministeredsafelywithatorvastatinincynomolgusmonkeysresultinginadditivelowdensitylipoproteincholesterolreductions |